Quick Answer
Korro Bio, Inc. reported Research And Development Expense of $65.58 million for the year ending 2025.
- Korro Bio, Inc. showed an increase of +3.0% in Research And Development Expense from 2024 to 2025.
- This data is from Korro Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $3.55 million | Q1 2019: $3.45 million | Q2 2019: $3.92 million | Q3 2019: $5.22 million | Q1 2020: $6.67 million | Q2 2020: $8.76 million | Q3 2020: $10.15 million | Q1 2021: $15.11 million | Q2 2021: $17.40 million | Q3 2021: $15.66 million | Q1 2022: $13.78 million | Q2 2022: $13.27 million | Q3 2022: $11.72 million | Q1 2023: $14.69 million | Q2 2023: $13.13 million | Q3 2023: $14.01 million | Q1 2024: $13.57 million | Q2 2024: $17.14 million | Q3 2024: $15.96 million | Q1 2025: $19.74 million | Q2 2025: $21.03 million | Q3 2025: $13.82 million.
- Over the full 9 years of available data (2017 to 2025), Korro Bio, Inc.'s Research And Development Expense has grown by 448.0%.
- Historical annual values: Fiscal year 2025: $65.58 million | Fiscal year 2024: $63.64 million | Fiscal year 2023: $57.25 million | Fiscal year 2022: $42.20 million | Fiscal year 2021: $60.92 million | Fiscal year 2020: $37.42 million | Fiscal year 2019: $18.78 million | Fiscal year 2018: $11.88 million | Fiscal year 2017: $11.97 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: